Disrupep

spanish biotech company

A DISRUPTIVE DRUG FOR THE PREVENTION AND TREATMENT OF PTSD
PREVALENCE AND CAUSES

Post Traumatic Stress Disorder: PTSD

GENERAL PREVALENCE
19-75% 75%
Physical/Sexual Aggression
52%
Accidents and Injuries
36%
Natural Disasters
30-40% 40%
Heart Conditions
12%
ICU Patients - post COVID19
25%

Exposed Personnel

UCI Covid 19 patients
11- 8%
Police, Health Care Workers, Firefighters…
11- 15%
Soldiers
(6-32%) 25%
UNTIL NOW

NO EFFECTIVE TREATMENT

PROCESS: Memory Consolidation, selective therapeutic window for PTSD
GREAT NEED of a causal approach, specific, efficient, short and economic to find a CURE!
Our Target: CPEB3
A protein that acts like an “switch” of long term memory.
CONCEPTUAL ADVANTAGES
Aimed at the cause of the illness (not just the symptoms). Impedes the consolidation of traumatic memory. Specific to long term memory (does not affect short term memory) Does not erase prior memories: only impedes the consolidation of new memories.

PROPOSED SOLUTION

QBP1 as an inhibitor of CPEB3 activation

The peptide QBP1 as prevention and therapy for PTSD

(OUR DRUG CANDIDATE)

Results of memory consolidation in mouse:

                                      Transgenic QBP1

Who we are

Team

Company with Technological Base (EBT), Spin-Off from CSIC

Dr. Mariano Carrión Vázquez (PhD)

Founding Partner

CSIC staff scientist at the Cajal Institute (Madrid) where he leads the Laboratory of Memory and Neurodegeneration.

Degree in Biology (specialty biochemistry) from the University of Valencia, Doctorate from the Universidad Autónoma de Madrid. 

Postdoctoral positions in the laboratory of Prof. Julio Fernández, in the Mayo Clínic (Rochester, MN, USA) and later as associate scientific in the University of Columbia (New York, NY, USA).

Important scientific merits.

Member of Scientific Advisory Board of the Fundación GADEA por la Ciencia

Dr. Ismael San Mauro Martín (PhD)

Founding Partner

Graduate in Nutrition and Dietetics, Doctor in Biomedicine from the Universidad Complutense de Madrid. Specialised in genomics, for the last 5 years directs the research group and CRO of CINUSA. More than 75 scientific publications.

Specialised in bringing drug candidates from the preclinical phase (animal model) to the clinical phase (humans). 

Serial Entrepreneur: partner of 5 companies, in the fields of health, biotechnology, science, agrofood

Marek Chauncey

Corporate/Investor Advisor
>25 years international experience in the pharmaceutical and biotechnology industry in product development; Business development and Corporate Management (ex CEO). Mentor in IESE Business School Executive Action Learning Team. Deep knowledge of research, product development, business development and cGMP manufacture. Advisor in fundraising, adquisitions and investments. EU Expert Evaluator.

Laboratory of " Molecular Bases of Memory and Neurodegeneration”

Future Hiring:

Post Doc:

PhD Students

Collaborators:

European Patent

Nº: 3280430

All search reports conducted indicate that the patent is “clean”: no competition. Feedom to Operate

RELATED ARTICLES (PUBLISHED and PENDING)

• López-García, P., et al and Carrión-Vázquez M. (enviado a publicar) (2020). Blockade of memory consolidation in mouse by an anti-amyloidogenic peptide. Reports the blocking of CPEB by QBP1 both in vitro and in vivo (in mouse). bioRxiv doi: 10.1101/2020.01.21.913053
• Hervás, R.,...and Carrión-Vázquez, M. (2016) Molecular basis of Orb2 amyloidogenesis and blockade of memory consolidation. PLoS Biology. doi: 10.1371/journal.pbio.1002361. Reports the blocking of consolidation of memory by QBP1 in Drosophila.
• Ramírez de Mingo D, Pantoja-Uceda D, Carrión-Vázquez M, Laurents DV (2020). Preferred conformations in the intrinsically disordered region of human CPEB3 explain its role in memory consolidation. bioRxiv doi:10.1101/2020.05.12.091587.
• Hervás, R., Fernández-Ramírez, M.C., Galera-Prat, A., Suzuki, M., Nagai, Y., Bruix, M., Menéndez, M., Laurents, D.V., and Carrión-Vázquez, M. (2020). Divergent CPEB prion-like domains reveal different assembly mechanisms for a generic amyloid-like fold. BioRxiv. DOI:10.1101/2020.05.19.103804.
• Ramos-Martín, F., Hervás, R., Carrión Vázquez, M & Laurents, D.V. (2014). Arch. Biochem. Biophys. 558:104-110. Reports the structure of QBP1 (by NMR).

contact with us

 

Dont like Filling up forms ? Mail us then

Dr. Mariano Carrión Vázquez
Dr. Ismael San Mauro Martín